Overview
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one.
Eligibility
Inclusion Criteria:
- Advanced or metastatic solid tumor malignancy
- Refractory to or intolerant of available therapies
- Evaluable or Measurable disease (RECIST 1.1 Criteria).
- ECOG Performance Status 0 or 1.
- Life expectancy > 3 months
Exclusion Criteria:
- Active brain metastasis or carcinomatous meningitis
- History of other malignancy within the past 2 years
- Significant cardiovascular disease within 6 months
- Significant gastrointestinal disease
- HIV infection with a CD4+ T-cell count < 200 cells/μL and/or a detectable viral load
- Liver dysfunction